Summit Therapeutics set to join Russell 3000® Index
08 juin 2021 07h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual...
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
03 juin 2021 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, June 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting,...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
17 mai 2021 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021....
Summit Therapeutics Announces Closing of $75 Million Rights Offering
12 mai 2021 14h59 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The rights offering...
Summit Therapeutics Publishes Scientific Updates to Corporate Website
06 mai 2021 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our...
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
05 mai 2021 12h47 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...
Summit Therapeutics Announces Commencement of Rights Offering
21 avr. 2021 08h04 HE
|
Summit Therapeutics Inc.
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
17 mars 2021 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on...
Summit Announces Intention to Redomicile its Holding Company to the United States
16 juil. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA, US, July 16, 2020 –...
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
06 févr. 2020 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment...